3Chen S O, Liu J Y, Zhang Q, et al. Clinical analysis, diagnosis and type division in 1125 patients with irritable bowel syndrom[J]. Am J Gastroenterol, 1993,88(9) : 1569 - 1572.
4Walker E A, Roy-byml P P, Kalon W J, et al. Irritable bowel syndrome and psychiatric illness[J]. Am J Psychiatry, 1990,147:566- 572.
5Evangelista S. Otilonium bromide, a selective spasmolytic for the gastrointestinal tract[J]. J Int Med Res, 1999,27(5):207 -222.
6Jackson J L, Malley P G, Tomkins, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis[J]. Am J Med, 2000,108(1) :65 - 72.
7Meir HK, Thomas R, William CD. Principles and practice of sleep medicine[M]. Third edition. Saunders Company, 2000. 676,679,681.
8James F,Carol D. Fluoxetine suppresse human cataplexy: a pilot study [J]. Neurology, 1994, 44: 707-709.
9Langdon N,Shindler J,Parkes JD, et al. Fluoxetine in the treatment of cataplexy[J]. Sleep, 1986,9 (2) :371-375.
6William BE. Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data [J]. Critical Reviews in Oncology/Hematology, 2006, 58 (1): 68.
7Monica MS, Miguel AC, Raquel de Paz, et al. Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab[J]. Leukemia Research, 2008, 32 (1): 199.
8Myrna CA, Lucely C, de la Garza J, et al. Clinical implications of gemcitabine in the treatment of cervical cancer[J]. Critical Reviews in Oncology/Hematology, 2007, 61(3): 230.
9Laurence B, Alain P, Nathalie D, et al. Emtricitabine: inhibitor and substrate of multidrug resistance associated protein [J]. European Journal of Pharmaceutical Sciences,2008, 35(4):247.
10Constantine GB, Richard LM, David YM, et al. Synthesis and anti-HIV activity of GS-9148 (2'-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor[J]. Bioorganic & Medicinal Chemistry Letters, 2008, 18(3): 1 120.
